BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide (15 amino acids) derived from a protein naturally found in gastric juice. It is studied extensively in animal models for accelerating healing of tendons, ligaments, muscles, bones, and intestinal tissue. It is not FDA-approved and is banned from 503A compounding pharmacies in the US.

Does BPC-157 actually work for healing?

Animal studies, primarily in rats and mice, show consistent and significant healing acceleration with BPC-157 — particularly for tendons, gut lining, and musculoskeletal tissue. Proposed mechanisms include VEGF upregulation, angiogenesis, and NO pathway modulation. However, no peer-reviewed human clinical trials have been published, so human efficacy and safety remain unproven. This is for educational reference only.

Can I buy BPC-157 legally in the US?

BPC-157 is listed on the FDA's prohibited bulk substances list for 503A compounding pharmacies (updated 2023), meaning licensed compounding pharmacies cannot legally prepare it. It is not FDA-approved. PeptIQ does not sell peptides and does not list vendors. Talk with a licensed clinician. Always verify current FDA and state regulations. This is not legal advice.

How do you reconstitute BPC-157?

To reconstitute BPC-157: Allow the lyophilized vial to reach room temperature. Add bacteriostatic water (BAC water — not saline) slowly down the vial's inner wall. Gently swirl — never shake — until fully dissolved (1–3 minutes). The solution should be clear and colorless. Store reconstituted BPC-157 refrigerated (2–8°C) and use within 28 days. Draw doses using an insulin syringe for subcutaneous injection.

What are the side effects of BPC-157?

BPC-157 is generally well-tolerated in animal research with no significant toxicity reported at studied doses. Reported effects in humans (anecdotal) include mild nausea at higher doses, injection site discomfort, and occasional dizziness. There are theoretical concerns about BPC-157's angiogenic effects potentially promoting tumor growth, though this has not been demonstrated in research. Consult a healthcare provider before use.

What is the typical BPC-157 dose?

Research protocols commonly discuss 250–500 mcg per day administered subcutaneously. Some protocols split this into 250 mcg twice daily. For gut-related issues, some researchers use oral administration (unfractionated peptide — limited absorption evidence). There is no FDA-approved dose. These are research protocols only — not medical advice.

BPC-157: Dosing, Side Effects & FDA Status

What is BPC-157?

BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a gastric juice protein, researched extensively for accelerating tissue healing, gut repair, and tendon recovery. Animal studies demonstrate dose-dependent healing of tendons, ligaments, bones, muscles, and intestinal tissue, along with anti-inflammatory and angiogenic effects. Not FDA-approved; placed on the FDA's 503A prohibited bulk substances list in 2023.

Mechanism of Action

Upregulates VEGF, EGF, and growth factor signaling; promotes angiogenesis; modulates nitric oxide (NO) synthase; activates FAK-paxillin and JAK-STAT pathways

Target: VEGF receptors, NO pathway, FAK-paxillin

Research / educational reference. Educational research index only — not medical advice. Literature maturity is not a verdict on whether a compound works in people. Community reports are not evidence of efficacy.

Evidence at a glance

Derived · maturity-1.0

Human efficacy is unproven unless an approved label or completed published efficacy program says otherwise. Counts reflect indexed literature volume/kind — never a verdict on effect.

Literature maturity

emerging 38/100

PubMed hits

223

CT.gov trials

Strong-human apps

Sample papers

Sample articles by era

pre-20182
2018-20204
2021-20236
2024-20267

Application grades (curated)

Human-grade apps0
Animal / in-vitro2
Mechanistic0

Does literature support studied applications?

Grades reflect cited literature posture — not a treatment recommendation. Community notes are never efficacy evidence.

Application	Cited evidence	Grade	Community
Soft-tissue healing (preclinical)	Multiple rodent studies report accelerated tendon/ligament/muscle healing signals.	Animal / in-vitro	Community reports vary; not evidence of efficacy.
Gastrointestinal mucosal protection (preclinical)	Animal models suggest cytoprotective effects in GI injury contexts.	Animal / in-vitro	Community reports vary; not evidence of efficacy.
Human clinical efficacy	Robust completed human efficacy RCTs are lacking for common wellness claims.	Anecdotal only	Community reports vary; not evidence of efficacy.

Pharmacology

Mechanism of action

•Upregulates VEGF, EGF, and growth factor signaling; promotes angiogenesis; modulates nitric oxide (NO) synthase; activates FAK-paxillin and JAK-STAT pathways
•Primary target framing: VEGF receptors, NO pathway, FAK-paxillin

Half-life

~4 hours

Identity & chemistry

CAS: 137525-51-0
PubChem: CID 9941957
Formula: C62H98N16O22
Molar mass: 1419.5 Da
InChIKey: HEEWEZGQMLZMFE-RKGINYAYSA-N

Identity cross-checked with PubChem where available. Compass HTML used only as a bootstrap checklist — not republished as product copy.

Storage & stability

Lyophilized: 2–8°C; lyophilized typical shelf 24+ months
Reconstituted: 2–8°C; in-use window often 28–45 days (product-dependent)
Tell-tale degradation: !Cloudiness, clumping, or particles after mixing
!Discoloration versus the expected clear/colorless (or labeled) solution
!Failed or incomplete reconstitution of lyophilized cake

Educational estimates. Prefer product labeling and peptide shelf-life tool.

Lab handling posture

Research / educational handling notes only. Not a substitute for an SDS.

•Use PPE appropriate for peptide powder/solution handling
•Avoid inhalation of lyophilized powder; handle spills per institutional policy
•Do not present research materials as medicines

Sample indexed literature

Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review.
Pharmaceuticals (Basel, Switzerland) · 2025 · PMID 40005999
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.
HSS journal : the musculoskeletal journal of Hospital for Special Surgery · 2025 · PMID 40756949
Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.
Alternative therapies in health and medicine · 2021 · PMID 34324435
Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing.
Cell and tissue research · 2019 · PMID 30915550
BPC 157 Rescued NSAID-cytotoxicity Via Stabilizing Intestinal Permeability and Enhancing Cytoprotection.
Current pharmaceutical design · 2020 · PMID 32445447
Stable Gastric Pentadecapeptide BPC 157 and Wound Healing.
Frontiers in pharmacology · 2021 · PMID 34267654

Research Indications

Tissue RepairMost Effective

Demonstrated acceleration of wound healing and soft tissue repair in research

Gut HealthEffective

Research shows beneficial effects on intestinal lining and GI function

Joint SupportEffective

Associated with reduced joint inflammation and improved mobility

Muscle RecoveryModerate

May support faster recovery from muscle strains and exercise stress

Research Protocols

These are commonly discussed research protocols — not medical advice. Consult a healthcare provider before use.

Goal	Dose	Frequency	Route
Starting Dose	250 mcg daily	Once daily	Subcutaneous injection
Standard Dose	500 mcg daily	Once daily	Subcutaneous injection
Split Dosing	250 mcg	Twice daily	Subcutaneous injection
Maintenance / Gut Protocol	250 mcg daily	Once daily (AM fasted)	Oral (research only)

Peptide & Drug Interactions

Always consult your healthcare provider before combining with other compounds. Use our Interaction Checker for reference.

TB-500 / BPC-157 (stack)Compatible

NSAIDs (Ibuprofen, Naproxen)Caution

CorticosteroidsCaution

AnticoagulantsMonitor

GH SecretagoguesCompatible

NAD+Compatible

How to Reconstitute & Inject

Use bacteriostatic (BAC) water only. Avoid saline — may cause precipitation. Refrigerate and use within 28 days.

1
Remove BPC-157 vial from refrigeration and allow to reach room temperature (15–20 minutes)
2
Clean vial top with alcohol swab and allow to air dry completely
3
Using a sterile syringe, draw the calculated volume of bacteriostatic water (BAC water)
4
Inject BAC water slowly down the side of the vial — do not aim directly at the powder
5
Gently swirl in circular motions — DO NOT shake vigorously as this degrades the peptide
6
Allow 2–3 minutes for full dissolution — solution should be clear and colorless
7
Draw calculated dose into an insulin syringe for subcutaneous injection
8
Inject into abdomen, thigh, or upper arm. Rotate injection sites to prevent lipodystrophy
9
Store reconstituted solution refrigerated (2–8°C) and use within 28 days

What to Expect

Week 1–2

Initial anti-inflammatory effects begin. Reduced pain and swelling in target area.

Week 2–4

Improved tissue mobility and reduced discomfort. Early healing acceleration.

Week 4–8

Significant recovery milestones. Stronger tissue repair and functional improvement.

Week 8–12

Near-complete healing in many cases. Improved strength and tissue integrity.

Side Effects & Safety

Generally well-tolerated in research settings
Mild nausea with higher doses
Injection site redness or discomfort
Rare: Dizziness or lightheadedness
Potential effect on blood pressure (monitor if hypertensive)

BPC-157 is not FDA-approved and cannot be prepared by 503A compounding pharmacies. PeptIQ does not sell peptides or list vendors. Talk with a licensed clinician.

FDA Status & Regulatory Info

Research Only

Rx Required: No

503A Ban: Yes

Telehealth: N/A

Full FDA Status Tracker

Frequently Asked Questions

Research References

External links for education only. We do not control third-party content.

Community-reported data

The information below reflects self-reported experiences from PeptIQ app users. It is not clinical evidence and should not replace professional medical advice.

Community Intelligence

What 128 users report

128 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 98% · Mixed 2% · Unfavorable overall 0%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Recovery

247

Energy

Sleep

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Nausea

Inflammation

Self-reported dose per injection

Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg

Reports span 0 to ≥ 5 mg (open-ended top bucket)

0–0.01 mg

0.025–0.05 mg

0.1–0.2 mg

0.2–0.4 mg

138

0.4–0.6 mg

0.6–1 mg

1–2 mg

3–5 mg

5+ mg

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Commonly stacked with

How repeat users are trending

Among repeat reporters, 94% said they felt similar to their last entry, 6% more positive, and 0% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 50 days · Based on 47 repeat reporters

Share Your Experience

Rate BPC-157 in the PeptIQ app and help the community make informed decisions.

Download PeptIQ Google Play

Educational information only

This page is for educational reference. It is not medical or legal advice. PeptIQ does not sell peptides or list vendors. Consult the FDA and a licensed healthcare professional for current regulations and individualized guidance.

BPC-157